Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FMDT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The award was issued on October 28, 2025, with an ultimate completion date of November 19, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is performing under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a broader $30.3 billion Defense Logistics Agency acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
The delivery order represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency, designated SPE2DR, which carries a $499.999 billion ceiling value through December 31, 2036. This underlying contract authorizes the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceuticals, including branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. DMS Pharmaceutical Group's established performance across numerous delivery orders and its designation as a critical pharmaceutical supplier positions the company to fulfill diverse specialized medical supply requirements for military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FMDT9?
SPE2DR26FMDT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FMDT9 worth?
The government has obligated $15,792 on SPE2DR26FMDT9.
Is contract SPE2DR26FMDT9 an order under another contract?
Yes. SPE2DR26FMDT9 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDT9 competed?
The extent of competition for SPE2DR26FMDT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award